NovoCure Limited (NVCR)
NASDAQ: NVCR · Real-Time Price · USD
12.12
-0.36 (-2.88%)
Apr 28, 2026, 4:00 PM EDT - Market closed

Company Description

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally.

Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.

NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.

NovoCure Limited
NovoCure logo
Country Switzerland
Founded 2000
IPO Date Oct 2, 2015
Industry Medical Devices
Sector Healthcare
Employees 1,605
CEO Frank Leonard

Contact Details

Address:
Neuhofstrasse 21
Baar, 6340
Switzerland
Website novocure.com

Stock Details

Ticker Symbol NVCR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001645113
CUSIP Number G6674U108
ISIN Number JE00BYSS4X48
SIC Code 3841

Key Executives

Name Position
Frank Leonard Chief Executive Officer
William F. Doyle Executive Chairman
Mukund Paravasthu Chief Operating Officer
Adam Daney Head of Investor Relations

Latest SEC Filings

Date Type Title
Apr 28, 2026 SCHEDULE 13G Filing
Apr 24, 2026 8-K/A [Amend] Current report
Apr 20, 2026 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 20, 2026 DEF 14A Other definitive proxy statements
Apr 9, 2026 8-K Current Report
Mar 26, 2026 SCHEDULE 13G/A Filing
Mar 26, 2026 8-K Current Report
Mar 5, 2026 144 Filing
Mar 4, 2026 144 Filing
Mar 4, 2026 144 Filing